ZENEO® Epinephrine
Anaphylaxis / Severe Allergy
Late-stage DevelopmentNDA 505(b)(2)
Key Facts
Indication
Anaphylaxis / Severe Allergy
Phase
Late-stage Development
Status
NDA 505(b)(2)
Company
About CROSSJECT
Crossject's mission is to revolutionize emergency drug delivery through its needle-free ZENEO® auto-injector platform, targeting critical situations where speed and ease-of-use are paramount. Its key achievement is a $60 million firm order from the U.S. BARDA for ZEPIZURE® (midazolam) for seizure rescue, with a total contract value potentially reaching $155 million. The strategy leverages a versatile 505(b)(2) regulatory pathway to build a portfolio of emergency therapies, transitioning from an R&D entity to a commercial-stage company with a primary focus on the U.S. market.
View full company profile